BioLineRx (NASDAQ:BLRX) versus Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Comparison

BioLineRx (NASDAQ:BLRX) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Valuation and Earnings

This table compares BioLineRx and Nurix Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18 million	6.31	-$1.17 million	($1.69)	-0.88
Nurix Therapeutics	$83.98 million	20.66	-$264.46 million	$2.31	6.87

BioLineRx has higher earnings, but lower revenue than Nurix Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Institutional & Insider Ownership

1.6% of BioLineRx shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares BioLineRx and Nurix Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Nurix Therapeutics	42.01%	49.34%	38.61%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BioLineRx and Nurix Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1	0	0	0	1.00
Nurix Therapeutics	1	0	14	0	2.87

Nurix Therapeutics has a consensus target price of $34.43, indicating a potential upside of 116.80%. Given Nurix Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Nurix Therapeutics is more favorable than BioLineRx.

Summary

Nurix Therapeutics beats BioLineRx on 12 of the 14 factors compared between the two stocks.

About BioLineRx

BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious medical conditions. The company is headquartered in Modi’in, Israel, and is listed on the Nasdaq Capital Market under the symbol BLRX. BioLineRx’s primary product is APHEXDA (motixafortide), a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.